Estrogen metabolites, level of E7, and squamous cell carcinoma antigenin the tissue of cervical cancer.

Frantsiyants, Elena M.; Комарова, Е. Ф.; Nikitina, Vera P.; Spiridonova, D.A.; Cheryarina, Natalia D.

doi:10.1200/jco.2014.32.15_suppl.e22236

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the ACC setting, it is important to evaluate any lengthening in the duration of PFS and OS. Nevertheless, frequent debate often occurs regarding the influence of the oestrogen, predominantly in the postmenopausal cohort [26][27][28]. To reduce the impact of oestrogen on survival in the present study, the primary strategy was to only include a postmenopausal cohort.…”

Section: Discussionmentioning

confidence: 99%

Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study

Xiao

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: The purpose of this study was to assess the efficacy and safety of cisplatin-based chemotherapy with or without bevacizumab (BEV) in Chinese women with advanced cervical cancer (ACC). Methods: For this observational study, we analysed the data of 316 Chinese women with ACC who were treated at the Henan provincial people's hospital between Jan 1, 2014, and Dec 31, 2018, with cisplatin-based chemotherapy plus BEV (CB) or cisplatin-based chemotherapy alone (CA) until disease progression, unacceptable toxicity, or death. The co-primary endpoints were overall survival (OS) and progression-free survival (PFS); the secondary endpoint was the occurrence of adverse events (AEs). Results: A total of 264 patients with ACC were included in the assessment (CB, n = 130 and CA, n = 134). At a median follow-up of 38 months (IQR 36-40), the median OS in the CB cohort was significantly longer than that in the CA cohort (hazard ratio [HR] 1.21, 95% confidence interval[CI] 1.14-1.73; p = 0.002); additionally, the median PFS was 345 days (95% CI, 318-372) for CB and 261 days (95% CI, 165-357) for CA(HR 1.61, 95% CI 1.12-2.17; p = 0.000). Significant differences were noted between groups in terms of thrombosis/embolism, neutropenia, and febrile neutropenia. Conclusions: In Chinese women with ACC, cisplatin-based chemotherapy plus BEV is associated with improved survival compared to cisplatin-based chemotherapy alone. This finding suggests a positive survival benefit of antiangiogenesis therapy in this population.

show abstract

Section: Discussionmentioning

confidence: 99%

Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study

Xiao

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

show abstract

Estrogen metabolites, level of E7, and squamous cell carcinoma antigenin the tissue of cervical cancer.

Cited by 1 publication

References 0 publications

Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study

Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study

Contact Info

Product

Resources

About